NewAmsterdam Pharma (NAMS) Institutional Ownership

89.89% of NewAmsterdam Pharma's stock is owned by institutional investors. Learn more on NAMS's institutional investor holdings.

Of the 165 institutional investors that purchased NewAmsterdam Pharma's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Wellington Management Group LLP ($6.38M), Frazier Life Sciences Management L.P. ($4.62M), Jennison Associates LLC ($4.31M), Deerfield Management Company L.P. Series C ($3.61M), Capital World Investors ($2.61M), Alliancebernstein L.P. ($2.33M), and RA Capital Management L.P. ($2.07M).

Institutional investors have bought a total of 19,006,700 shares in the last 24 months. This purchase volume represents approximately $548.24M in transactions.

Of the 53 institutional investors that sold NewAmsterdam Pharma's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Bain Capital Life Sciences Investors LLC ($3.41M), Viking Global Investors LP ($2.77M), Jennison Associates LLC ($2.47M), Fcpm Iii Services B.V. ($1.43M), Pictet Asset Management Holding SA ($1.29M), Cormorant Asset Management LP ($1.18M), and Adage Capital Partners GP L.L.C. ($1.17M).

Institutional investors have sold a total of 18,986,651 shares in the last 24 months. This volume of shares sold represents approximately $605.45M in transactions.